Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.
Also called NCT01994109
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 187 participants
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
- Registry
-
NCT01994109
-
- Other papers using this trial's data
- Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Russia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01994109. Randomized; quadruple masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2019-08-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
- Acronym
- MYSTICOL
- Condition
- Sialorrhea
- Intervention (Drug)
- MYOBLOC
- Intervention (Other)
- PLACEBO
- Lead sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Record details
- Record id
cardio:ct-nct01994109- Content hash
07d36a1a902dbf1b8069aed1157d25e894eb43326fab4c697d12366eb2d3f1b3